B. Metzler seel. Sohn & Co. Holding AG Takes Position in Agilent Technologies, Inc. (NYSE:A)

B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Agilent Technologies, Inc. (NYSE:A) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 17,004 shares of the medical research company’s stock, valued at approximately $2,137,000.

Several other hedge funds also recently made changes to their positions in A. First Allied Advisory Services Inc. bought a new stake in Agilent Technologies during the 3rd quarter worth approximately $267,000. ExodusPoint Capital Management LP bought a new stake in Agilent Technologies during the 3rd quarter worth approximately $245,000. State of Tennessee Treasury Department increased its stake in Agilent Technologies by 51.5% during the 3rd quarter. State of Tennessee Treasury Department now owns 96,153 shares of the medical research company’s stock worth $9,706,000 after purchasing an additional 32,667 shares in the last quarter. Lombard Odier Asset Management Switzerland SA increased its stake in Agilent Technologies by 9.9% during the 3rd quarter. Lombard Odier Asset Management Switzerland SA now owns 12,886 shares of the medical research company’s stock worth $1,301,000 after purchasing an additional 1,158 shares in the last quarter. Finally, Earnest Partners LLC increased its stake in Agilent Technologies by 8.3% during the 3rd quarter. Earnest Partners LLC now owns 359,279 shares of the medical research company’s stock worth $36,266,000 after purchasing an additional 27,421 shares in the last quarter.

Shares of Agilent Technologies stock opened at $129.34 on Thursday. The business has a fifty day simple moving average of $123.46 and a two-hundred day simple moving average of $116.46. Agilent Technologies, Inc. has a 1 year low of $72.75 and a 1 year high of $136.98. The company has a market capitalization of $39.41 billion, a price-to-earnings ratio of 56.24, a P/E/G ratio of 3.82 and a beta of 1.04. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.33 and a quick ratio of 1.84.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Monday, February 15th. The medical research company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.17. Agilent Technologies had a return on equity of 21.02% and a net margin of 13.47%. The business had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter last year, the firm posted $0.81 EPS. As a group, equities analysts anticipate that Agilent Technologies, Inc. will post 3.67 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 28th. Shareholders of record on Tuesday, April 6th will be issued a dividend of $0.194 per share. This represents a $0.78 annualized dividend and a yield of 0.60%. The ex-dividend date of this dividend is Monday, April 5th. Agilent Technologies’s dividend payout ratio is 23.78%.

Agilent Technologies declared that its board has authorized a stock repurchase program on Tuesday, February 16th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 5% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

A number of research firms recently issued reports on A. KeyCorp increased their target price on Agilent Technologies from $130.00 to $148.00 in a research note on Wednesday, February 17th. Robert W. Baird upped their price target on Agilent Technologies from $133.00 to $137.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 17th. MKM Partners assumed coverage on Agilent Technologies in a research report on Wednesday, December 23rd. They set a “buy” rating and a $57.00 price target for the company. SVB Leerink upped their price target on Agilent Technologies from $130.00 to $140.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 17th. Finally, Redburn Partners raised Agilent Technologies from a “neutral” rating to a “buy” rating in a research report on Friday, March 19th. Nine equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $105.40.

In other Agilent Technologies news, CEO Michael R. Mcmullen sold 21,212 shares of the stock in a transaction on Monday, February 1st. The stock was sold at an average price of $120.26, for a total transaction of $2,550,955.12. Following the transaction, the chief executive officer now owns 356,963 shares in the company, valued at approximately $42,928,370.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael Tang sold 500 shares of the stock in a transaction on Thursday, January 14th. The stock was sold at an average price of $127.27, for a total value of $63,635.00. Following the transaction, the senior vice president now owns 54,880 shares in the company, valued at approximately $6,984,577.60. The disclosure for this sale can be found here. Insiders have sold a total of 22,712 shares of company stock valued at $2,742,090 in the last ninety days.

About Agilent Technologies

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.

Recommended Story: Secondary Public Offerings

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.